Tag: ultra-rare models

AI, ML and Automation Use-Cases That Unlock Value in Rare/Ultra-Rare Development Models AI, ML and Automation Use-Cases That Unlock Value in Rare/Ultra-Rare Development Models The development of treatments for rare and ultra-rare diseases presents unique challenges and opportunities within clinical research. Unveiling the potential of Artificial Intelligence (AI), Machine Learning (ML), and automation can significantly…

Read More “AI, ML and Automation Use-Cases That Unlock Value in Rare/Ultra-Rare Development Models” »

Risk Management and Stage-Gate Governance for Rare/Ultra-Rare Development Models Risk Management and Stage-Gate Governance for Rare/Ultra-Rare Development Models The landscape of pharmaceutical R&D has undergone significant transformation, particularly in the realm of rare and ultra-rare disease development. With an increasing number of organizations venturing into these niches, understanding the intricacies of risk management and effective…

Read More “Risk Management and Stage-Gate Governance for Rare/Ultra-Rare Development Models” »

IP, Exclusivity and Deal-Making Implications of Strong Rare/Ultra-Rare Development Models Understanding Rare and Ultra-Rare Diseases Rare and ultra-rare diseases, defined as conditions affecting fewer than 200,000 and 1,000 individuals respectively in the US, present unique challenges in clinical trials and drug development. These diseases often lack sufficient epidemiological data, making it difficult to establish effective…

Read More “IP, Exclusivity and Deal-Making Implications of Strong Rare/Ultra-Rare Development Models” »

Sustainability, ESG and Green R&D Considerations in Rare/Ultra-Rare Development Models Sustainability, ESG and Green R&D Considerations in Rare/Ultra-Rare Development Models The pharmaceutical and biotechnology sectors face unique challenges in developing treatments for rare and ultra-rare diseases. As we move towards a more sustainable future, integrating Environmental, Social, and Governance (ESG) principles into research and development…

Read More “Sustainability, ESG and Green R&D Considerations in Rare/Ultra-Rare Development Models” »

Roadmap: 12–24 Month Plan to Upgrade Your Organization’s Rare/Ultra-Rare Development Models Roadmap: 12–24 Month Plan to Upgrade Your Organization’s Rare/Ultra-Rare Development Models The development of therapies for rare and ultra-rare diseases presents unique challenges and opportunities for pharmaceutical companies and clinical research organizations. This step-by-step tutorial guide offers a comprehensive roadmap to modernize your organization’s…

Read More “Roadmap: 12–24 Month Plan to Upgrade Your Organization’s Rare/Ultra-Rare Development Models” »

How Rare/Ultra-Rare Development Models Supports Precision Medicine and Biomarker-Driven Trials The landscape of pharmaceutical research and development has undergone significant transformation in recent years, especially in the realm of rare and ultra-rare diseases. Precision medicine, fueled by advancements in biomarker discovery, is now an attainable goal, providing a pathway to innovative therapeutic solutions. This article…

Read More “How Rare/Ultra-Rare Development Models Supports Precision Medicine and Biomarker-Driven Trials” »

Emerging Science and Technology Trends Redefining Rare/Ultra-Rare Development Models In the ever-evolving landscape of pharmaceutical research and development, significant advancements are being made in the approach to rare and ultra-rare disease clinical trials. This article delves into emerging science and technology trends that are redefining the development models associated with day 1 labs clinical trials,…

Read More “Emerging Science and Technology Trends Redefining Rare/Ultra-Rare Development Models” »

Talent, Skills and Operating Models Needed to Deliver on Rare/Ultra-Rare Development Models Talent, Skills and Operating Models Needed to Deliver on Rare/Ultra-Rare Development Models In the complex landscape of pharmaceutical research and development (R&D), the emergence of rare and ultra-rare diseases presents unique challenges and opportunities. As a consequence, clinical operations, regulatory affairs, medical affairs,…

Read More “Talent, Skills and Operating Models Needed to Deliver on Rare/Ultra-Rare Development Models” »

Using Real-World Data and RWE to Strengthen Rare/Ultra-Rare Development Models Decisions The development of innovative therapies for rare and ultra-rare diseases presents unique challenges within the pharmaceutical landscape. Efficacious decision-making in this area necessitates a robust understanding of both clinical and real-world data (RWD). This comprehensive tutorial aims to provide clinical operations, regulatory affairs, medical…

Read More “Using Real-World Data and RWE to Strengthen Rare/Ultra-Rare Development Models Decisions” »

Scenario Planning and Portfolio Strategy Anchored in Rare/Ultra-Rare Development Models Understanding Rare and Ultra-Rare Diseases in Clinical Trials The landscape of clinical trials is continuously evolving, particularly in the domain of rare and ultra-rare diseases. Rare diseases are defined by the European Medicines Agency (EMA) as conditions affecting fewer than 5 in 10,000 people in…

Read More “Scenario Planning and Portfolio Strategy Anchored in Rare/Ultra-Rare Development Models” »